Integral Health Asset Management LLC Makes New Investment in COMPASS Pathways plc (NASDAQ:CMPS)

Integral Health Asset Management LLC acquired a new stake in shares of COMPASS Pathways plc (NASDAQ:CMPS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 200,000 shares of the company's stock, valued at approximately $756,000. Integral Health Asset Management LLC owned approximately 0.29% of COMPASS Pathways at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Altium Capital Management LLC acquired a new stake in shares of COMPASS Pathways during the fourth quarter worth $5,384,000. Nantahala Capital Management LLC increased its holdings in COMPASS Pathways by 400.0% during the 4th quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company's stock worth $3,780,000 after purchasing an additional 800,000 shares in the last quarter. Balyasny Asset Management L.P. bought a new position in COMPASS Pathways during the 4th quarter worth about $2,458,000. Affinity Asset Advisors LLC raised its stake in shares of COMPASS Pathways by 183.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 850,512 shares of the company's stock valued at $3,215,000 after purchasing an additional 550,000 shares during the period. Finally, Marshall Wace LLP bought a new stake in shares of COMPASS Pathways in the fourth quarter valued at about $1,395,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

COMPASS Pathways Stock Performance

CMPS stock traded up $0.09 during mid-day trading on Thursday, hitting $3.95. 399,303 shares of the company were exchanged, compared to its average volume of 800,409. The business has a 50 day simple moving average of $3.34 and a 200-day simple moving average of $3.99. The stock has a market capitalization of $366.75 million, a PE ratio of -1.80 and a beta of 2.27. COMPASS Pathways plc has a 1-year low of $2.49 and a 1-year high of $8.54. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. On average, equities analysts forecast that COMPASS Pathways plc will post -2.33 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on CMPS shares. Canaccord Genuity Group lowered their price objective on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, February 28th. Stifel Nicolaus started coverage on shares of COMPASS Pathways in a research report on Thursday, February 27th. They set a "buy" rating and a $11.00 price target on the stock. Cantor Fitzgerald upgraded COMPASS Pathways to a "strong-buy" rating in a report on Tuesday. HC Wainwright reiterated a "buy" rating and set a $45.00 target price on shares of COMPASS Pathways in a report on Monday. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $18.00 price target on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $20.20.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.